Viviane Monges joins the Board of Directors of Novo Holdings. Göran Ando and Per Wold-Olsen did not seek re-election.
At the Annual General Meeting of Novo Holdings on Friday, Viviane Monges was elected as a new member of the Board of Directors.
Viviane Monges is a senior global finance executive who has had a diverse and international career, mostly in the pharmaceutical industry. She is an independent board director of UCB, a global biopharmaceutical company, and a member of the Strategic Board of NeoMedLight, which develops medical devices for phototherapy.
She joined Wyeth Pharmaceuticals in 1997 and held several leadership roles, including CFO for the Europe Region and CFO of the Global Pharma business unit. From 2006 to 2010, Viviane was with Novartis OTC as Europe CFO and then as Global Division CFO. In 2010, she joined Galderma, a multinational dermatology company acquired by Nestlé. As Group CFO of Nestlé Skin Health, she contributed to rapid growth and several major acquisitions. From 2015, she served as CFO of the Nestlé Business Excellence Division, driving a major transformation project focused on business solutions, processes and efficiency.
Sten Scheibye, Chairman of the Board of Directors of Novo Holdings, says: “I am delighted that Viviane Monges is joining the Board of Novo Holdings. Viviane Monges has an impressive career and her extensive business experience will be of great value to Novo Holdings as we aim to further increase our investments in the life sciences.”
Göran Ando and Per Wold-Olsen did not seek re-election as members of the Board of Directors.
“I would like to thank Göran Ando and Per Wold-Olsen for their important contributions to the Board. Having served on the Board since 2006 and 2011, respectively, they have played a major part in the development of Novo Holdings,” says Sten Scheibye.
Novo Holdings is the holding company of the Novo Group. The company today announced income and investment returns of DKK 20.7 billion (EUR 2.8 billion) in 2017.
About Viviane Monges
Born in France
2015–2017: CFO, Nestlé Business Excellence Division
2010–2015: CFO, Galderma/Nestlé Skin Health
2006–2010: Europe CFO and Global Division CFO, Novartis OTC
1997–2006: Wyeth Pharmaceuticals, Global Pharma and EMEA CFO
Board and other appointments
2017–: independent board member, UCB
2014–: board member, NeoMedLight
BA and MBA in Finance and Public Administration, ESCP Europe, Paris, France
About Novo Holdings A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets.
In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.
It is the vision of Novo Holdings to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novoholdings.dk.
Christian Mostrup Scheel, Senior Press Officer, phone: +45 3067 4805, email@example.com